How High Can Prices Go? Cell and Gene Therapies
Curious how high prices can go in cell and gene therapies? Read our white paper to learn more about developments in the cell and gene therapy payer world.
China’s NRDL 2022 Update: Spotlight on Rare Disease (Part 3 of 3)
With negotiated prices as much as 95% below launch pricing, marketing rare disease therapies in China is a challenge. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan discuss alternate access channels. Download the free brief (part 3 of 3).
China NRDL 2022 Update – Spotlight on Oncology (Part 2 of 3)
Recent updates to China’s NRDL have a big impact on oncology therapies. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan explain what that means for multinationals in this free brief (part 2 of 3).
China’s NRDL 2022 Update: A Snapshot and Overall Trends (Part 1 of 3)
In China’s rapidly growing pharma market, the NRDL is the main path to market access. And it’s changed. PRECISIONadvisors Chloe Wang, Katherine Leong, and Cherry Moldovan explain what the updates mean for multinationals in this free brief (part 1 of 3).
White Paper: “Preventative” Gene Therapies: Perspectives on Payer Access Challenges and Solutions
Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.
What Changes Can We Expect on Health Care in the Coming General Elections in Spain?
What changes can we expect on health care in the coming general elections in Spain? Following up on our previous post, we have some insights on what lies ahead for the coming general elections in Spain.
What you need to know about key stakeholders and P&MA dynamics in Latin America for 2023 and beyond
Latin America is a $43 billion pharma market—and regional dynamics matter. PRECISIONadvisor’s dedicated team of experts can help navigate local market access and pricing. Discover what that means for your brand.
Hear From Key Stakeholders: The Future Treatment and Access Landscape for Cell & Gene Therapies Roundtable
Earlier this year, Precision Value & Health, in association with Precision ADVANCE, hosted an in-depth, live roundtable: The Future Treatment and Access Landscape for Cell and Gene Therapies
Hear From Key Stakeholders: The Future Treatment and Access Landscape for Cell & Gene Therapies Roundtable
Earlier this year, Precision Value & Health, in association with Precision ADVANCE, hosted an in-depth, live roundtable: The Future Treatment and Access Landscape for Cell and Gene Therapies
FDA announces launch of Project FrontRunner
Earlier this year, the FDA announced plans to launch Project FrontRunner to support manufacturers in prioritizing the development of cancer drugs in early treatment lines, partly in response to issues that have arisen with the current accelerated approval scheme. In this #Access90 video, Precision's Dominika Meszarosova discusses the issues that Project Frontrunner seeks to address and the critical need for early dialogue, incentives and close collaboration with manufacturers to ensure success.
